## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($234.54)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. Humana Working With Mark Cuban on Potential Pharmacy Partnership**
- Source: Bloomberg Law News | 20251204T193744 | Somewhat-Bullish | Relevance: 100%
- Humana Inc. is exploring a potential pharmacy partnership with billionaire Mark Cuban's Cost Plus Drugs company, according to recent statements from Cuban and Humana's CEO. This collaboration could increase pressure on established pharmacy benefit managers. While details are scarce, the focus appears to be on direct-to-employer programs, leveraging Cuban's transparent mail-order drug sales and Humana's expanding CenterWell pharmacy division.

**2. Humana working with Mark Cuban on potential pharmacy partnership**
- Source: Modern Healthcare News | 20251204T145100 | Somewhat-Bullish | Relevance: 100%
- Humana is reportedly in discussions with Mark Cuban to develop direct-to-employer pharmacy programs. This partnership aims to streamline the drug supply chain by bypassing traditional intermediaries. The initiative could significantly impact how employers provide pharmaceutical benefits to their employees.

**3. Humana Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163000 | Bullish | Relevance: 100%
- Humana Inc. (HUM) stock experienced a significant rise of 6.18% on a strong trading day for the overall stock market. This increase to $256.92 broke a three-day losing streak for the company. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, indicating a favorable market session.

**4. Berman Tabacco Announces Investigation of Humana, Inc. (NYSE:HUM)**
- Source: GlobeNewswire | 20251202T153100 | Bearish | Relevance: 100%
- Berman Tabacco has announced an investigation into potential stockholder claims against Humana, Inc. (NYSE:HUM) following allegations that the company paid illegal kickbacks to insurance brokers like SelectQuote between 2016 and 2021. These alleged kickbacks, possibly totaling up to $250 million, were intended to steer insurance customers towards Humana's Medicare offerings. The investigation will examine whether Humana's board members, officers, and/or directors breached their fiduciary duties, especially after shares declined approximately 3% upon the unsealing of the complaint in May 2025.

**5. Humana Inc Reaffirms 2025 Earnings Guidance**
- Source: TradingView | 20251202T032530 | Bullish | Relevance: 100%
- Humana Inc. reaffirmed its 2025 earnings guidance during investor meetings on December 1, 2025. The company projected a reaffirmed FY 2025 EPS guidance of $12.26 and an adjusted EPS of $17.00. Potential changes are expected in GAAP EPS due to strategic initiatives.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 3)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-25 | Barclays | $234 | $245 | -4% |
| 2025-11-10 | Truist Securiti | $285 | $300 | -5% |
| 2025-11-07 | Deutsche Bank | $231 | $250 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-25 | Barclays | main | Equal-Weight |
| 2025-11-10 | Truist Securiti | main | Hold |
| 2025-11-07 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.14M) |
| Sells | 6 ($1.54M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +4.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (3 target cuts vs 0 raises). Insider selling cluster ($1.5M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $31.1B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 20.3 |
| Current P/E | 14.8 |
| YoY Growth | -27.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.1% to 3.3% (+4.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.7pp (needs >4.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. AM_20 at 5.4% shows strong absolute momentum above own 20MA. Outperforming sector by 4.8pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (3.50), confirming momentum. RSI neutral at 52. OFD pattern: -SBN (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.27% (CS: 76) | Neutral |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | 3.50 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 0.964x | Below |
| vs SMA200 | 0.978x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $253.02
- **Stop Loss:** $234.54 (7.3% risk)
- **Target:** $289.98 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $6,831.54
- **Portfolio %:** 6.83%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*